Maria Jure–Kunkel

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang et al. · Cancer Immunology Immunotherapy · 2011 · 777 citations · Full text

Medicine, Immunology, Oncology +10

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

Alfonso R. Sánchez-Paulete, Francisco J. Cueto, María Martínez‐López et al. · Cancer Discovery · 2015 · 476 citations · Full text

Life Sciences, Immunology, Oncology +17

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi et al. · Clinical Cancer Research · 2016 · 412 citations · Full text

Medicine, Oncology, Pharmacology +17

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Joseph F. Grosso, Maria Jure–Kunkel · PubMed · 2013 · 341 citations

Life Sciences, Immunology, Oncology +17